Speakers

Adam J. Adler, Ph.D., Professor, Immunology, University of Connecticut

Prasad S. Adusumilli, M.D., FACS, Deputy Chief of Translational & Clinical, Research, Thoracic Surgery, Memorial Sloan-Kettering Cancer Center

Omar Ali, Ph.D., Staff Scientist, Wyss Institute for Biologically Inspired Engineering, Harvard University

Robert Anders, M.D., Ph.D., Associate Professor, Pathology, Johns Hopkins University

Philip M. Arlen, M.D., President & CEO, Precision Biologics, Inc.

Roy D. Baynes, M.D., Ph.D., Senior Vice President and Head, Global Clinical Development, Merck Research Laboratories

Stephen Beers, Ph.D., Associate Professor, Cancer Immunology and Immunotherapy, University of Southampton

John Bell, Ph.D., Senior Scientist, Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Professor, Departments of Medicine and Biochemistry, Microbiology & Immunology, University of Ottawa

Kevin Bonham, Ph.D., Curriculum Fellow, Microbiology and Immunobiology Department, Harvard Medical School

Chris Boshoff, M.D., Ph.D., Vice President and Head, Early, Development, Translational and Immuno-Oncology, Pfizer

Adrian Bot, M.D., Ph.D., Vice President, Translational Sciences, R&D, Kite Pharma Inc.

Caroline Breitbach, Ph.D., Vice President, Translational Development, Turnstone Biologics

Joshua Brody, M.D., Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai

Tullia Bruno, Ph.D., Research Assistant Professor, Immunology, University of Pittsburgh

Manel Cascallo, Ph.D., Co-Founder, President and CEO, VCN Biosciences

Saso Cemerski, Ph.D., Associate Principal Scientist, Merck Research Laboratories

Edward Cha, M.D., Ph.D., Associate Medical Director, Cancer Immunotherapy Franchise, Genentech

Brian Champion, Ph.D., Senior Vice President, R&D, PsiOxus Therapeutics Ltd

Zhao Chen, Ph.D., Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

Yeong “Christopher” Choi, Ph.D., Director, TCPF and Assistant Professor of Oncology, Center for Immunotherapy, Roswell Park Cancer Institute

Robert Coffin, Ph.D., CEO, Replimmune

Joe Conner, Ph.D., CSO, Virttu Biologics

Michael A. Curran, Ph.D., Assistant Professor, Immunology; Scientific Director, ORBIT Platform MD Anderson Cancer Center

Adil Daud, M.D., Professor, Hematology/Oncology, University of California, San Francisco; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Anthony Davies, Ph.D., COO, 4D Molecular Therapeutics

John Desjarlais, Ph.D., CSO, Xencor

Luis Alberto Diaz, M.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Gianpietro Dotti, M.D., Professor, Microbiology and Immunology, University of North Carolina

Jakob Dupont, M.D., Senior Vice President & CMO, OncoMed Pharmaceuticals

Kenneth Emancipator, M.D., Executive Medical Director, Companion Diagnostics, Merck & Co.

Boris Engels, Ph.D., Investigator, Exploratory Immuno-Oncology, Novartis Institutes for Biomedical Research

Andrew M. Evens, D.O., Professor and Chief, Hematology/Oncology, Tufts University School of Medicine; Director, Tufts Cancer Center

Christopher R. Heery, M.D., Director, Clinical Trials Group, Laboratory of Tumor Immunology, Center for Cancer Research

Christian S. Hinrichs, MD, Investigator, Experimental Transplantation and Immunology Branch, Lasker Clinical Research Scholar, NIH

Mark J. Federspiel, Ph.D., Professor and Director, Viral Vector Production Laboratory, Mayo Clinic

Patrick Forde, M.D., Assistant Professor, Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Morganna Freeman, D.O., Medical Oncologist, Immunotherapeutics, The Angeles Clinic and Research Institute

Bruce Freimark, Ph.D., Research Director, Preclinical Oncology, Peregrine Pharmaceuticals

Jennifer Gansert, Ph.D., Executive Director, Global Development Lead, Amgen, Inc.

Sanja Gauthier, M.D., Senior Medical Director, Medical Safety Evaluation, Pharmacovigilance and Patient Safety, AbbVie

Tariq Ghayur, Ph.D., Distinguished Research Fellow, AbbVie Bioresearch Center  

Geoffrey T. Gibney, M.D., Medical Oncologist, Georgetown-Lombardi Comprehensive Cancer Center

Sacha Gnjatic, Ph.D., Associate Professor, Tisch Cancer Institute, Hematology/Oncology, Immunology, Icahn School of Medicine at Mount Sinai

Matthew J. Goldstein, M.D., Ph.D., Director, Translational Medicine, Neon Therapeutics, Inc.

Jeffrey Hanke, Ph.D., CSO, Tesaro

Ronald Herbst, Ph.D., Vice President, R&D; Head, Oncology Research, MedImmune

Alex Yee-Chen Huang, M.D., Ph.D., Associate Professor, Pediatrics, Pathology & Biomedical Engineering, Case Western Reserve University School of Medicine  

Ella Ioffe, Ph.D., Associate Director, Immune-Oncology, Regeneron Pharmaceuticals

Pushpa Jayaraman, Ph.D., Investigator II, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

Suchit Jhunjhunwala, Ph.D., Scientist, Bioinformatics, Genentech

Frank R. Jones, Ph.D., Chairman & CEO, Etubics Corporation

Jennifer C. Jones, M.D., Ph.D., Assistant Clinical Investigator, Molecular Immunogenetics & Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health

Karin Jooss, Ph.D., CSO, Gritstone Oncology

Pawel Kalinski, M.D., Ph.D., Professor, Surgery, Immunology, and Bioengineering, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute

Cris Kamperschroer, Ph.D., Associate Research Fellow, Drug Safety R&D, Pfizer

Vassiliki Karantza, M.D., Ph.D., Senior Director, Clinical Research Oncology, Merck Research Laboratories

Noriyuki Kasahara, M.D., Ph.D., Professor, Departments of Cell Biology and Pathology, Co-Leader, Viral Oncology Program, University of Miami

David Kaufman, Ph.D., Executive Director, Clinical Oncology, Merck Research Laboratories

Howard L. Kaufman, M.D., FACS, Associate Director, Clinical Sciences, Rutgers Cancer Institute of New Jersey; Professor and Chief, Division of Surgical Oncology, Rutgers Robert Wood Johnson Medical School

Llew Keltner, M.D., Ph.D., CEO, EPISTAT

Arthur M. Krieg, M.D. CEO, Checkmate Pharmaceuticals

David Kirn, M.D., CEO & Co-Founder, 4D Molecular Therapeutics; Adjunct Professor, Bioengineering, University of California, Berkeley

Keith L. Knutson, Ph.D., Professor, Immunology, Mayo Clinic

David M. Kranz, Ph.D., Phillip A. Sharp Professor of Biochemistry, University of Illinois

Arthur M. Krieg, M.D. CEO, Checkmate Pharmaceuticals

Kyle Landgraf, Ph.D., Senior Scientist, Discovery Research, AvidBiotics

Jane Lebkowski, Ph.D., President & CSO, Research and Development, Asterias Biotherapeutics

Michael Lim, M.D., Associate Professor, Neurosurgery, Oncology and Radiation Oncology, Johns Hopkins University School of Medicine

Douglas Linn, Ph.D., Senior Scientist, In Vivo Pharmacology, Merck

Konstantin M. Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLP

Jason J. Luke, M.D., FACP, Assistant Professor, Medicine, Melanoma and Developmental Therapeutics Clinics, University of Chicago Medical Center

Ravi Madan, M.D., Clinical Director, Genitourinary Malignancies, Branch, National Cancer Institute, National Institutes of Health

Jennifer Mataraza, Ph.D., Senior Investigator, Immune Oncology, Novartis Institutes for BioMedical Research

Patricia McCoon, Ph.D., Principal Scientist, Oncology IMED Translational Science, AstraZeneca Pharmaceuticals

Miriam Merad, M.D., Ph.D., Chair, Cancer Immunology, Oncological Sciences, Tisch Cancer Institute, Mount Sinai Hospital  

Jan ter Meulen, M.D., Dr.habil., DTM&H, CSO, Immune Design

Richard A. Morgan, Vice President, Immunotherapy, bluebird bio

Spyro Mousses, Ph.D., President, Systems Imagination Inc.

Matthew Mulvey, Ph.D., CEO, BeneVir

Kuldeep Neote, Ph.D., Senior Director, New Ventures, J&J Innovation Center Boston

Cokey Nguyen, Ph.D., Vice President, R&D, Enumeral

Fares Nigim, M.D., Massachusetts General Hospital

Patrick Alexander Ott, M.D., Ph.D., Assistant Professor, Medicine, Dana-Farber Cancer Institute

Michael J. Overman, M.D., Associate Professor, Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center

Joseph Pearlberg, M.D., Ph.D., Senior Medical Director, Infinity Pharmaceuticals

Rodney Prell, Ph.D., DABT, Principal Scientist/Toxicologist, Safety Assessment, Genentech

Maire Quigley, Ph.D., Research Investigator, Cell Process Development, Cell & Gene Therapies, Novartis

Laszlo Radvanyi, Ph.D., Senior Vice President; Head of Immuno-Oncology Translational Innovation Platform (TIP), EMD Serono

Sheila Ranganath, Ph.D., Associate Director, R&D, Enumeral Biomedical Corporation

Paul Rennert, Ph.D., President & CSO, Aleta Biotherapeutics Inc.

Aaron Ring, M.D., Ph.D., Assistant Professor, Immunobiology, Yale University School of Medicine

Scott Rodig, M.D., Ph.D., Associate Professor, Pathology, Harvard Medical School; Associate Pathologist, Pathology, Brigham & Women’s Hospital

Arjan Roozen, Vice President, GMP Solutions & Manufacturing, Cellectis

Michael Rosenzweig, Ph.D., Executive Director, Biology-Discovery, IMR Early, Discovery, Merck Research Laboratories

Stephen J. Russell, M.D, Ph.D., Professor, Mayo Clinic

Catherine Sabatos-Peyton, Ph.D., Senior Investigator, Novartis Institutes for BioMedical Research

Christian Schmees, Ph.D., Head of Tumor Biology, Molecular Biology Department, NMI Natural and Medical Sciences Institute at the University of Tübingen

Taylor Schreiber, M.D., Ph.D., CSO, Heat Biologics, Inc.

Armon Sharei, Ph.D., CEO, SQZ Biotechnologies

Michail Sitkovsky, Ph.D., Professor, Eleanor W. Black Chair, and Director, New England Inflammation and Tissue Protection Institute, Northeastern University

Craig L. Slingluff, Jr., M.D., Joseph Helms Farrow Professor of Surgery; Vice-Chair for Research; Director, Human Immune Therapy Center, University of Virginia School of Medicine

Susan R. Slovin, M.D., Ph.D., Medical Oncologist, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center

Elena Spanjaard, Ph.D., Director, Worldwide Research & Development, Regulatory Affairs, Pfizer

David M. Spencer, Ph.D., CSO, Bellicum Pharmaceuticals

Pramod K. Srivastava, Ph.D., M.D., Professor, Immunology and Medicine, Director, Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine

Zhen Su, M.D., MBA, Senior Vice President, Global Head of Medical Affairs Oncology, EMD Serono

Brad Thompson, Ph.D., CEO, Oncolytics Biotech

Stephen Thorne, Ph.D., Professor and Scientific Advisor, Inventor, Western Oncolytics

Wolfgang Uckert, Associate Professor, Department of Cell Biology and Gene Therapy, Humboldt University Berlin

Marit van Buuren, Ph.D., Scientist, Immunology, Neon Therapeutics

Andrea van Elsas, Ph.D., CSO, Aduro Biotech Europe, The Netherlands

Janaki Veeraraghavan, Ph.D., Biologist, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, FDA

Luis M. Vence, Ph.D., Scientific Manager, Immunology, MD Anderson Cancer Center

Alena Gros Vidal, Ph.D., Research Fellow, Surgery Branch, National Cancer Institute

Antti Vuolanto, Ph.D., Executive Vice President, Targovax

Jeffrey Wallin, Ph.D., Group Leader, Early Stage Oncology Biomarker Development, Genentech

Steffen Walter, Ph.D., CSO, Immatics Biotechnologies GmbH

Chan Whiting, Ph.D., Director, Immune Monitoring/Biomarker Development, Aduro Biotech

Jon Wigginton, M.D., CMO & Senior Vice President, Clinical Development, MacroGenics

Andy Williams, Ph.D., Companion Diagnostics Group Leader, Cancer Immune Therapies, Genentech

Daniel Williams, Head, UK Research Operations, Adaptimmune

K. Dane Wittrup, Ph.D., Carbon P. Dubbs Professor, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology

James E. Wooldridge, M.D., CSO, Immuno-Oncology Clinical Development, Eli Lilly and Company

John Wrangle, M.D., Assistant Professor, Medicine, Hematology/Oncology, Medical University of South Carolina

Jianda Yuan, M.D., Ph.D., Director, Translational Immuno-Oncology Research, Merck Research Labs

Jonathan Zalevsky, Ph.D., Vice President, Biology & Preclinical Development, Nektar Therapeutics

Xingxing Zang, Ph.D., Associate Professor, Microbiology and Immunology & Medicine, Albert Einstein College of Medicine